| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Cell Growth & Differentiation, Vol 4, Issue 7 563-569, Copyright © 1993 by American Association of Cancer Research
ARTICLES |
S Rong, M Oskarsson, D Faletto, I Tsarfaty, JH Resau, T Nakamura, E Rosen, RF Hopkins 3d and GF Vande Woude
ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Maryland 21702.
We have previously shown that, in mouse NIH/3T3 cells, it is necessary to coexpress the gene for human hepatocyte growth factor/scatter factor (HGF/SFhu) with its receptor, the human met protooncogene (methu), to activate the transforming activity of the receptor (S. Rong, M. Bodescot, D. Blair, T. Nakamura, K. Mizuno, M. Park, A. Chan, S. Aaronson, and G. F. Vande Woude, Mol. Cell. Biol., 12: 5152-5158, 1992). In this study, we report that exceptionally high levels of the ligand and its receptor are expressed in tumor cell explants after several tumor passages through nude mice. Confluent tumor cells explanted after the second passage in nude mice can express 1700 units/ml/10(6) cells/72 h of scatter activity as determined in Madin-Darby canine kidney cell scatter assays. The motogenic factor produced by these cells is easily purified by heparin-Sepharose chromatography, and the purified factor efficiently induces tyrosine phosphorylation of Methu in YaOvBix2NMA human ovarian carcinoma cells. To account for the unusually high level of HGF/SFhu and Methu expression, we propose that normal levels of Methu receptor are inefficient at transducing the signal(s) required for transformation of mouse cells. Therefore, high levels of Methu receptor are required for tumorigenesis, and corresponding high levels of the ligand are required to induce the signal. Consistent with this model, endogenous mouse scatter factor is not detected in conditioned medium from cells transformed by overexpression of the Metmu receptor.
This article has been cited by other articles:
 |
|
 |
|
  C.-F. Gao, Q. Xie, Y.-W. Zhang, Y. Su, P. Zhao, B. Cao, K. Furge, J. Sun, K. Rex, T. Osgood, et al. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: Inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma Mol. Cancer Ther., October 1, 2009; 8(10): 2803 - 2810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Tiran, A. Oren, C. Hermesh, G. Rotman, Z. Levine, H. Amitai, T. Handelsman, M. Beiman, A. Chen, D. Landesman-Milo, et al. A Novel Recombinant Soluble Splice Variant of Met Is a Potent Antagonist of the Hepatocyte Growth Factor/Scatter Factor-Met Pathway Clin. Cancer Res., July 15, 2008; 14(14): 4612 - 4621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zhao, T. Grabinski, C. Gao, R. S. Skinner, T. Giambernardi, Y. Su, E. Hudson, J. Resau, M. Gross, G. F. Vande Woude, et al. Identification of a Met-Binding Peptide from a Phage Display Library Clin. Cancer Res., October 15, 2007; 13(20): 6049 - 6055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Francone, R. G. Landmann, C.-T. Chen, M. Y. Sun, E. J. Kuntz, Z. Zeng, R. P. Dematteo, P. B. Paty, and M. R. Weiser Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met-expressing tumors Mol. Cancer Ther., April 1, 2007; 6(4): 1460 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Leibowitz-Amit, G. Tsarfaty, Y. Abargil, G. M. Yerushalmi, J. Horev, and I. Tsarfaty Mimp, a Mitochondrial Carrier Homologue, Inhibits Met-HGF/SF-Induced Scattering and Tumorigenicity by Altering Met-HGF/SF Signaling Pathways. Cancer Res., September 1, 2006; 66(17): 8687 - 8697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hecht, M. Papoutsi, H. D. Tran, J. Wilting, and L. Schweigerer Hepatocyte Growth Factor/c-Met Signaling Promotes the Progression of Experimental Human Neuroblastomas Cancer Res., September 1, 2004; 64(17): 6109 - 6118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Christensen, R. Schreck, J. Burrows, P. Kuruganti, E. Chan, P. Le, J. Chen, X. Wang, L. Ruslim, R. Blake, et al. A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes in Vitro and Exhibits Cytoreductive Antitumor Activity in Vivo Cancer Res., November 1, 2003; 63(21): 7345 - 7355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. C. Ma, T. Kijima, G. Maulik, E. A. Fox, M. Sattler, J. D. Griffin, B. E. Johnson, and R. Salgia c-MET Mutational Analysis in Small Cell Lung Cancer: Novel Juxtamembrane Domain Mutations Regulating Cytoskeletal Functions Cancer Res., October 1, 2003; 63(19): 6272 - 6281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. V. Hay, B. Cao, R. S. Skinner, L.-M. Wang, Y. Su, J. H. Resau, B. S. Knudsen, M. F. Gustafson, H.-M. Koo, G. F. V. Woude, et al. Radioimmunoscintigraphy of Human Met-Expressing Tumor Xenografts Using Met3, a New Monoclonal Antibody Clin. Cancer Res., September 1, 2003; 9(10): 3839s - 3844s. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. Dekel, S. Biton, G. M. Yerushalmi, R. T. Altstock, L. Mittelman, D. Faletto, N. I. Smordinski, and I. Tsarfaty In situ activation pattern of Met docking site following renal injury and hypertrophy Nephrol. Dial. Transplant., August 1, 2003; 18(8): 1493 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Dekel, S. Biton, G. M. Yerushalmi, R. T. Altstock, L. Mittelman, D. Faletto, N. I. Smordinski, and I. Tsarfaty In situ activation pattern of Met docking site following renal injury and hypertrophy Nephrol. Dial. Transplant., August 1, 2003; 18(88): 1493 - 1504. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. E. Hammond, S. Carter, J. McCullough, S. Urbe, G. Vande Woude, and M. J. Clague Endosomal Dynamics of Met Determine Signaling Output Mol. Biol. Cell, April 1, 2003; 14(4): 1346 - 1354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-N. Qian, X. Guo, B. Cao, E. J. Kort, C.-C. Lee, J. Chen, L.-M. Wang, W.-Y. Mai, H.-Q. Min, M.-H. Hong, et al. Met Protein Expression Level Correlates with Survival in Patients with Late-stage Nasopharyngeal Carcinoma Cancer Res., January 1, 2002; 62(2): 589 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Gmyrek, M. Walburg, C. P. Webb, H.-M. Yu, X. You, E. D. Vaughan, G. F. Vande Woude, and B. S. Knudsen Normal and Malignant Prostate Epithelial Cells Differ in Their Response to Hepatocyte Growth Factor/Scatter Factor Am. J. Pathol., August 1, 2001; 159(2): 579 - 590. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. Cao, Y. Su, M. Oskarsson, P. Zhao, E. J. Kort, R. J. Fisher, L.-M. Wang, and G. F. Vande Woude Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models PNAS, June 19, 2001; 98(13): 7443 - 7448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Shaharabany, R. Abramovitch, T. Kushnir, G. Tsarfaty, M. Ravid-Megido, J. Horev, R. Ron, Y. Itzchak, and I. Tsarfaty In Vivo Molecular Imaging of Met Tyrosine Kinase Growth Factor Receptor Activity in Normal Organs and Breast Tumors Cancer Res., June 1, 2001; 61(12): 4873 - 4878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Otsuka, J. Jakubczak, W. Vieira, D. P. Bottaro, D. Breckenridge, W. J. Larochelle, and G. Merlino Disassociation of Met-Mediated Biological Responses In Vivo: the Natural Hepatocyte Growth Factor/Scatter Factor Splice Variant NK2 Antagonizes Growth but Facilitates Metastasis Mol. Cell. Biol., March 15, 2000; 20(6): 2055 - 2065. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. A. Taylor, E. Hudson, J. H. Resau, and G. F. Vande Woude Regulation of P311 Expression by Met-Hepatocyte Growth Factor/Scatter Factor and the Ubiquitin/Proteasome System J. Biol. Chem., February 11, 2000; 275(6): 4215 - 4219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Webb, C. D. Hose, S. Koochekpour, M. Jeffers, M. Oskarsson, E. Sausville, A. Monks, and G. F. Vande Woude The Geldanamycins Are Potent Inhibitors of the Hepatocyte Growth Factor/Scatter Factor-Met-Urokinase Plasminogen Activator-Plasmin Proteolytic Network Cancer Res., January 1, 2000; 60(2): 342 - 349. [Abstract] [Full Text]
|
|
|
|
|
|
S. Koochekpour, M. Jeffers, P. H. Wang, C. Gong, G. A. Taylor, L. M. Roessler, R. Stearman, J. R. Vasselli, W. G. Stetler-Stevenson, W. G. Kaelin Jr., et al. The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells Mol. Cell. Biol., September 1, 1999; 19(9): 5902 - 5912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chausovsky, I. Tsarfaty, Z. Kam, Y. Yarden, B. Geiger, and A. D. Bershadsky Morphogenetic Effects of Neuregulin (Neu Differentiation Factor) in Cultured Epithelial Cells Mol. Biol. Cell, November 1, 1998; 9(11): 3195 - 3209. [Abstract] [Full Text]
|
|
|
|
 |
|
 X.-M. Yang, J. G. Toma, S. X. Bamji, D. J. Belliveau, J. Kohn, M. Park, and F. D. Miller Autocrine Hepatocyte Growth Factor Provides a Local Mechanism for Promoting Axonal Growth J. Neurosci., October 15, 1998; 18(20): 8369 - 8381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Trusolino, G. Serini, G. Cecchini, C. Besati, F. S. Ambesi-Impiombato, P. C. Marchisio, and R. De Filippi Growth Factor-dependent Activation of {alpha}v{beta}3 Integrin in Normal Epithelial Cells: Implications for Tumor Invasion J. Cell Biol., August 24, 1998; 142(4): 1145 - 1156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jeffers, L. Schmidt, N. Nakaigawa, C. P. Webb, G. Weirich, T. Kishida, B. Zbar, and G. F. Vande Woude Activating mutations for the Met tyrosine kinase receptor in human cancer PNAS, October 14, 1997; 94(21): 11445 - 11450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kauma, N. Hayes, and S. Weatherford The Differential Expression of Hepatocyte Growth Factor and Met in Human Placenta J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 949 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Takayama, W. J. LaRochelle, R. Sharp, T. Otsuka, P. Kriebel, M. Anver, S. A. Aaronson, and G. Merlino Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor PNAS, January 21, 1997; 94(2): 701 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Taylor, M. Jeffers, D. A. Largaespada, N. A. Jenkins, N. G. Copeland, and G. F.V. Woude Identification of a Novel GTPase, the Inducibly Expressed GTPase, That Accumulates in Response to Interferon gamma J. Biol. Chem., August 23, 1996; 271(34): 20399 - 20405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Tsarfaty, S Rong, J. Resau, S Rulong, P. da Silva, and G. Vande Woude The Met proto-oncogene mesenchymal to epithelial cell conversion Science, January 7, 1994; 263(5143): 98 - 101. [Abstract] [PDF]
|
|
|
|
 |
|
 S Bellusci, G Moens, J. Thiery, and J Jouanneau A scatter factor-like factor is produced by a metastatic variant of a rat bladder carcinoma cell line J. Cell Sci., January 5, 1994; 107(5): 1277 - 1287. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Rong and G.F. Vande Woude Autocrine Mechanism for met Proto-oncogene Tumorigenicity Cold Spring Harb Symp Quant Biol, January 1, 1994; 59(0): 629 - 636. [Abstract] [PDF]
|
|
|
|
|
|
S.-L. Lee, R. B. Dickson, and C.-Y. Lin Activation of Hepatocyte Growth Factor and Urokinase/Plasminogen Activator by Matriptase, an Epithelial Membrane Serine Protease J. Biol. Chem., November 17, 2000; 275(47): 36720 - 36725. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
